KingBZhangXHarchaWG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial (published correction appears in Lancet. 2023;401(10392):1928. doi:10.1016/S0140-6736(23)01078-4). Lancet. 2023;401(10387):1518-1529. doi:10.1016/S0140-6736(23)00222-2
2.
ZhangXJiangY.Predictors and management of inadequate response to JAK inhibitors in alopecia areata. Am J Clin Dermatol. 2024;25(6):975-986. doi:10.1007/s40257-024-00884-x
3.
HébertVJolyP.Major improvement of very severe alopecia areata in patients treated with the combination of baricitinib and low doses of corticosteroids: an eight-case series. Clin Exp Dermatol. 2023;48(11):1258-1259. doi:10.1093/ced/llad239
4.
ZhangWLiXChenBZhangJTorres-CulalaKMTZhouC.Oral tofacitinib and systemic corticosteroids, alone or in combination, in patients with moderate-to-severe alopecia areata: a retrospective study. Front Med. 2022;9:891434. doi:10.3389/fmed.2022.891434
5.
KingBMirmiraniPLo SiccoK, et al. Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme. J Eur Acad Dermatol Venereol. 2025;39(6):1163-1173. doi:10.1111/jdv.20547
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
